|
1.
|
|
13 p, 3.0 MB |
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
/
Albanell Mestres, Joan (Hospital del Mar (Barcelona, Catalunya)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez, Leticia C. (Complejo Hospitalario Universitario de A Coruña) ;
López-Muñiz, José Ignacio Chacón (Hospital Virgen de la Salud (Toledo)) ;
Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ;
de Juan Ferre, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Del Barco Berrón, Sonia (Institut Català d'Oncologia) ;
Pérez, Y.F. (Hospital Universitario Central de Asturias) ;
Mata, J.G. (Hospital Santa María Nai en Ourense) ;
Palomo, A.G. (Complejo Asistencial de León) ;
Gregori, J.G. (Fundació Institut Valencià d'Oncologia) ;
Pardo, P.G. (Hospital Universitari Vall d'Hebron) ;
Mañas, J.J.I. (Complejo Hospitalario de Navarra) ;
Hernández, A.L. (Hospital Clínic Universitari (València)) ;
de Dueñas, E.M. (Consorci Hospitalari Provincial de Castelló) ;
Jáñez, N.M. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Murillo, S.M. (Hospital Universitari Arnau de Vilanova) ;
Bofill, J.S. (Hospital Universitario Nuestra Señora de Valme) ;
Auñón, P.Z. (Hospital Universitario La Paz (Madrid)) ;
Sanchez-Rovira, P. (Complejo Hospitalario de Jaén) ;
Universitat Autònoma de Barcelona
Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. [...]
2017 -  10.1007/s12094-016-1520-2
Clinical & Translational Oncology, Vol. 19 Núm. 2 (january 2017) , p. 149-161
|
|
|
2.
|
|
22 p, 8.7 MB |
Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer
/
Waryah, Charlene (University of Western Australia) ;
Cursons, Joseph (Monash University, Australia) ;
Foroutan, Momeneh (Department of Biochemistry and Molecular Biology. Monash University, Australia) ;
Pflueger, Christian (University of Western Australia) ;
Wang, Edina (University of Western Australia) ;
Molania, Ramyar (University of Melbourne, Australia) ;
Woodward, Eleanor (Harry Perkins Institute of Medical Research, Australia) ;
Sorolla, Anabel (University of Western Australia) ;
Wallis, Christopher (University of Western Australia) ;
Moses, Colette (University of Amsterdam, The Netherlands) ;
Glas, Irina (Harry Perkins Institute of Medical Research, Australia) ;
Magalhães, Leandro (University of Pará, Brazil) ;
Thompson, Erik W. (Queensland University of Technology, Brisbane, Australia) ;
Fearnley, Liam G. (University of Melbourne, Australia) ;
Chaffer, Christine L. (St Vincent's Clinical School. UNSW Medicine, Australia) ;
Davis, Melissa (University of Melbourne, Australia) ;
Papenfuss, Anthony T. (University of Melbourne, Australia) ;
Redfern, Andrew (University of Western Australia) ;
Lister, Ryan (The University of Western Australia) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blancafort, Pilar (University of Western Australia)
Epithelial-mesenchymal transition (EMT) is a reversible transcriptional program invoked by cancer cells to drive cancer progression. Transcription factor ZEB1 is a master regulator of EMT, driving disease recurrence in poor-outcome triple negative breast cancers (TNBCs). [...]
2023 - 10.1002/advs.202301802
Advanced science, Vol. 10 Núm. 22 (august 2023)
|
|
|
3.
|
|
10 p, 2.5 MB |
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
/
Gil-Gil, M.J. (Institut Català d'Oncologia) ;
Bellet Ezquerra, Meritxell (Hospital Universitari Vall d'Hebron) ;
Bergamino, M. (Institut Català d'Oncologia) ;
Morales, S. (Hospital Arnau de Vilanova (València)) ;
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Saura, Cristina (Hospital Universitari Vall d'Hebron) ;
Fernández-Ortega, A. (Institut Català d'Oncologia) ;
Garcia-Martinez, E. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martinez-Jañez, N. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Melé, M. (Hospital Sant Joan) ;
Villagrasa, P. (SOLTI Breast Cancer Research Group) ;
Céliz, Pamela (SOLTI Breast Cancer Research Group) ;
Perez Martin, X. (Institut Català d'Oncologia. L'Hospitalet) ;
Ciruelos, Eva (Department of Medical Oncology. Hospital) ;
Pernas, S. (Institut Català d'Oncologia)
Background: The CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other cardiovascular risk factors in whom conventional doxorubicin was contraindicated. [...]
2021 - 10.3389/fonc.2021.645026
Frontiers in Oncology, Vol. 11 (september 2021) , p. 645026
|
|
|
4.
|
|
25 p, 4.8 MB |
Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide
/
Cámara-Sánchez, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Díaz Riascos, Zamira Vanessa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García Aranda, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gener, Petra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Giani-Alonso, Micaela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Royo, Miriam (Institut de Química Avançada de Catalunya) ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Schwartz, Simon (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona.
Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí"
Cancer maintenance, metastatic dissemination and drug resistance are sustained by cancer stem cells (CSCs). Triple negative breast cancer (TNBC) is the breast cancer subtype with the highest number of CSCs and the poorest prognosis. [...]
2022 - 10.3390/ijms231911760
International journal of molecular sciences, Vol. 23, Issue 19 (October 2022) , art. 11760
|
|
|
5.
|
|
19 p, 6.6 MB |
Design and synthesis of a novel non peptide CN-NFATc signaling inhibitor for tumor suppression in triple negative breast cancer
/
Sánchez-Morales, Adrià (Universitat Autònoma de Barcelona. Departament de Química) ;
Biçer, Atilla (Institut d'Investigació Biomèdica de Bellvitge) ;
Panagiotopoulos, Vasilis (University of West Attica. Department of Biomedical Engineering) ;
Crecente-Garcia, Selma (Universitat Autònoma de Barcelona. Departament de Química) ;
Benaiges Miñarro, Cristina (Universitat Autònoma de Barcelona. Departament de Química) ;
Bayod, Sergi (Parc Científic de Barcelona) ;
Hernández, José Luís (Parc Científic de Barcelona) ;
Busqué Sánchez, Félix (Universitat Autònoma de Barcelona. Departament de Química) ;
Matsoukas, Minos-Timotheos (University of West Attica. Department of Biomedical Engineering) ;
Pérez-Riba, Mercè (Institut d'Investigació Biomèdica de Bellvitge) ;
Alibes, Ramón (Universitat Autònoma de Barcelona. Departament de Química)
The Ca2/calmodulin-mediated phosphatase activity of calcineurin (CN) integrates calcium-mediated signaling with gene expression programs involved in the control of essential cellular processes in health and disease, such as the immune response and the pathogenesis of cancer progression and metastasis. [...]
2022 - 10.1016/j.ejmech.2022.114514
European Journal of Medicinal Chemistry, Vol. 238 (August 2022) , art. 114514
|
|
|
6.
|
|
9 p, 2.9 MB |
Study and Preparation of Multifunctional Poly(L-Lysine)@Hyaluronic Acid Nanopolyplexes for the Effective Delivery of Tumor Suppressive MiR-34a into Triple-Negative Breast Cancer Cells
/
Djafari, Jamila (Nova University Lisbon. Chemistry Department) ;
Fernández-Lodeiro, Javier (Proteomass Scientific Society) ;
Santos, Hugo M. (Proteomass Scientific Society) ;
Lorenzo Rivera, Julia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Rodriguez-Calado, Sergi (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Bértolo, Emilia (Canterbury Christ Church University) ;
Capelo-Martínez, José Luis (Proteomass Scientific Society) ;
Lodeiro, Carlos (Proteomass Scientific Society)
Non-viral gene delivery using exogenous microRNAs is a potential strategy for fighting cancers with poor prognosis and which lack specific therapies, such as triple-negative breast cancer (TNBC). Herein we report the synthesis of six nontoxic electrostatic polymeric nanocapsules (P1 to P6) for microRNA delivery in TNBC cells. [...]
2020 - 10.3390/ma13235309
Materials, Vol. 13, Issue 23 (December 2020) , art. 5309
|
|
|
7.
|
|
11 p, 362.2 KB |
BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort
/
Rofes, Paula (Centro de Investigación Biomédica en Red de Cáncer) ;
Del Valle, Jesús (Centro de Investigación Biomédica en Red de Cáncer) ;
Torres Esquius, Sara (Vall d'Hebron Institut d'Oncologia) ;
Feliubadaló, Lidia (Centro de Investigación Biomédica en Red de Cáncer) ;
Stradella, Agostina (Institut Català d'Oncologia) ;
Moreno-Cabrera, José Marcos (Centro de Investigación Biomédica en Red de Cáncer) ;
López-Doriga, Adriana (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Munté, Elisabet (Centro de Investigación Biomédica en Red de Cáncer) ;
de Cid, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Campos, Olga (Institut Català d'Oncologia) ;
Cuesta, Raquel (Institut Català d'Oncologia) ;
Teulé, Álex (Institut Català d'Oncologia) ;
Grau, Èlia (Institut Català d'Oncologia) ;
Sanz, Judit (Althaia Xarxa Assistencial Universitària de Manresa) ;
Capellá, G. (Gabriel) (Centro de Investigación Biomédica en Red de Cáncer) ;
Diez, Orland (Vall d'Hebron Institut d'Oncologia) ;
Brunet, Joan (Universitat de Girona) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Lázaro, Conxi (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1-associated ring domain 1 (BARD1), nuclear partner of BRCA1, has been suggested as a potential HBOC risk gene, although its prevalence and penetrance are variable according to populations and type of tumor. [...]
2021 - 10.3390/genes12020150
Genes, Vol. 12 (january 2021)
|
|
|
8.
|
|
13 p, 2.0 MB |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
/
Garrido-Castro, Ana (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ;
Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ;
Guo, Hao (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Data Sciences) ;
Ciruelos, Eva (Hospital Universitario 12 de Octubre (Madrid)) ;
Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ;
Gavilá, Joaquin (Fundació Institut Valencià d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré Brunet, Laia (SOLTI Breast Cancer Research Group) ;
Céliz, Pamela (SOLTI Breast Cancer Research Group) ;
Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ;
Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ;
Savoie, Jennifer (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Xu, Zhan (Northern Arizona University. School of Communication) ;
Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ;
Krop, Ian E. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Solit, David B. (Memorial Sloan Kettering Cancer Center) ;
Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ;
Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ;
Winer, Eric P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Lin, Nancy U. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ;
Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)
|
|
|
9.
|
|
33 p, 1.1 MB |
Engineering a nanostructured nucleolin-binding peptide for intracellular drug delivery in triple-negative breast cancer stem cells
/
Pesarrodona Roches, Mireia (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Sánchez-García, Laura (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Seras-Franzoso, Joaquin (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez Chardi, Alejandro (Universitat Autònoma de Barcelona. Servei de Microscòpia) ;
Baltà Foix, Ricardo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Cámara-Sánchez, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gener, Petra (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jara, José Juan (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Pulido, Daniel (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Serna, Naroa (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Schwartz, Simó (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Royo, Miriam (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Abasolo, Ibane (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Universitat Autònoma de Barcelona.
Departament de Genètica i de Microbiologia
Five peptide ligands of four different cell surface receptors (nucleolin, CXCR1, CMKLR1, and CD44v6) have been evaluated as targeting moieties for triple-negative human breast cancers. Among them, the peptide F3, derived from phage display, promotes the fast and efficient internalization of a genetically fused green fluorescent protein (GFP) inside MDA-MB-231 cancer stem cells in a specific receptor-dependent fashion. [...]
2020 - 10.1021/acsami.9b15803
ACS applied materials & interfaces, Vol. 12, Issue 5 (February 2020) , p. 5381-5388
2 documents
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
